Literature DB >> 21185797

[Familial hypocalciuric hypercalcemia: a new mutation].

M Ubetagoyena Arrieta1, L Castaño González, G Pérez de Nanclares Leal, D Arruebarrena Lizarraga, M Imaz Murguiondo, R Areses Trapote.   

Abstract

Familial hypocalciuric hypercalcemia (FHH) is a cause of hypercalcemia with autosomal dominant pattern of inheritance and high penetrance. In most of the cases it can be shown to be due to an inactivating mutation on the gene coding for the calcium-sensing receptor (CaSR). Heterozygous cases usually do not present symptoms and they are diagnosed as an incidental finding. We report three affected children with an inactivating heterozygous mutation, p.Phe789del, in exon 7 of the calcium-sensing receptor gene (CASR gene), situated in chromosome 3q21 (Ensembl ENSG00000036828), which results in elevated serum calcium, normal o high level of parathyroid hormone (PTH) and reduced urinary excretion with hypocalciuria. It is very important to determine the difference between FHH and primary hyperparathyroidism. Therefore, in a mild to moderate PTH-dependent hypercalcemia we must perform a family study and determine the urinary excretion of calcium. The presence of any other affected family member or reduced urinary calcium excretion is enough to suspect FHH, and this should be confirmed by the mutational analysis of the CASR gene, in order to establish the correct diagnosis, differentiated from primary hyperparathyroidism, to avoid unnecessary investigations or operations.
Copyright © 2010 Asociación Española de Pediatría. Published by Elsevier Espana. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21185797     DOI: 10.1016/j.anpedi.2010.10.001

Source DB:  PubMed          Journal:  An Pediatr (Barc)        ISSN: 1695-4033            Impact factor:   1.500


  1 in total

1.  Familial hypocalciuric hypercalcemia: new mutation in the CASR gene converting valine 697 to methionine.

Authors:  Cristina Aparicio López; Pilar Anton-Martin; Belén Gil-Fournier; Soraya Ramiro-León; Gustavo Pérez-Nanclares; Guiomar Pérez de Nanclares; Beatriz Martínez Menéndez; Luis Castaño
Journal:  Eur J Pediatr       Date:  2011-06-04       Impact factor: 3.183

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.